Nutriband Inc. (NASDAQ: NTRB) reported first-quarter revenue of $667,000, representing a significant 63% increase compared to the same period last year. The revenue growth stems from expanded kinesiology tape production through its Pocono Pharma subsidiary and increased retail presence at major retailers including Target, Walmart, Walgreens, and CVS.
The pharmaceutical development company is simultaneously advancing its AVERSA Fentanyl project, an abuse-deterrent transdermal opioid patch designed to prevent drug misuse and diversion. A recently formalized partnership with Kindeva Drug Delivery will help share development costs and provide milestone payments as the product progresses toward regulatory approval.
Market projections suggest the AVERSA Fentanyl patch could generate between $80 million and $200 million in annual U.S. sales. The patch incorporates Nutriband's proprietary AVERSA technology, which can be integrated into transdermal patches to mitigate risks of abuse, misuse, and accidental exposure for drugs with high potential for misappropriation.
By pursuing both expanded retail distribution and innovative pharmaceutical development, Nutriband demonstrates a strategic approach to growing shareholder value across multiple market segments.
